Prezista Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

RESIST-2: 2nd-line ART for HIV-2 Infection
Condition:   HIV-2 Infection Interventions:   Diagnostic Test: HIV-2 Genotypic Drug Resistance Testing using DBS;   Drug: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID);   Drug: 2nd line ART (Tenofovir DF 300mg QD + La mividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID );   Drug: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg...
Source: ClinicalTrials.gov - January 9, 2018 Category: Research Source Type: clinical trials